Paradigm Biopharmaceuticals (ASX:PAR) Accounts Payable & Accrued Expense : A$9.99 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Paradigm Biopharmaceuticals Accounts Payable & Accrued Expense?

Paradigm Biopharmaceuticals's quarterly accounts payable & accrued expense declined from Dec. 2022 (A$13.67 Mil) to Jun. 2023 (A$12.16 Mil) and declined from Jun. 2023 (A$12.16 Mil) to Dec. 2023 (A$9.99 Mil).

Paradigm Biopharmaceuticals's annual accounts payable & accrued expense increased from Jun. 2021 (A$4.99 Mil) to Jun. 2022 (A$7.09 Mil) and increased from Jun. 2022 (A$7.09 Mil) to Jun. 2023 (A$12.16 Mil).

Paradigm Biopharmaceuticals Accounts Payable & Accrued Expense Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Accounts Payable & Accrued Expense Chart

Paradigm Biopharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

2.32

2.78

4.99

7.09

12.16

Paradigm Biopharmaceuticals Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial												13.33	7.09	13.67	12.16	9.99

Paradigm Biopharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Paradigm Biopharmaceuticals (ASX:PAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

PBIGF:USA

Address

500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000

Website

https://www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).